Mesothelioma is a rare neoplasm arising from mesothelial cells that line the serous membranes. The pleura is the most commonly affected site, whereas the peritoneum is the second most frequent location, accounting for approximately 10-15% of all mesotheliomas, equivalent to only a few hundred new cases annually in the United States. Unlike pleural … [Read more...]
A Rare Case of Pleural Deciduoid Mesothelioma With Histological, Immunohistochemical, Fluorescent In Situ Hybridization, and Ultrastructural Findings
Abstract: Owing to the rarity of deciduoid mesotheliomas, few studies have reported detailed morphological analyses. Here, we report a case of deciduoid mesothelioma along with cytological, histological, immunohistochemical, fluorescent in situ hybridization (FISH), and electron microscopic findings. The patient was a 75-year-old man with a … [Read more...]
Pleurectomy/Decortication Safe in Select Patients With Pleural Mesothelioma
Pleurectomy/decortication can be completed safely in select patients with pleural mesothelioma with low postoperative mortality, according to findings from a study published in The Annals of Thoracic Surgery. “Our findings show that pleurectomy/decortication can be done safely when patients are carefully selected and surgery is tailored to … [Read more...]
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Treatments: CheckMate 743 Study [Opdivo plus Yervoy treatments have] demonstrated long-term, durable survival benefit as first-line treatment in patients with various solid tumor types. The randomized phase III CheckMate 743 study demonstrated significant overall survival (OS) benefit with [Opdivo plus … [Read more...]
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
Background: Pembrolizumab (anti-PD-1 antibody) plus lenvatinib (multityrosine kinase inhibitor) showed high clinical activity in PEMMELA cohort 1 in patients with pleural mesothelioma pre-treated with platinum-based chemotherapy. This study (cohort 2) aimed to investigate the clinical activity of this combination in patients with pleural … [Read more...]
Pericardial Mesothelioma: Diagnostic and Therapeutic Management, a Population-Based Study in Italy
Pericardial mesothelioma (PM) is an extremely rare tumour for which only case reports, small case series, and case reviews have been published. This is a large population-based study on PM in Italy using data from the Italian National Mesothelioma Registry (Registro Nazionale Mesoteliomi, ReNaM). Information collected includes detailed clinical … [Read more...]
Pleural Mesothelioma Diagnosis for the Pulmonologist: Steps Along the Way
Background/Objectives: Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis and complex diagnostic pathways. Pulmonologists often play a central role in its initial recognition and investigation. This narrative review synthesizes the current evidence on [mesothelioma diagnosis], with emphasis on imaging, tissue … [Read more...]
A Case of Primary Malignant Peritoneal Mesothelioma
Primary malignant mesothelioma (MPM) is a rare malignancy that arises from the epithelial cells that line visceral cavities. The primary pleural presentation is known as the most commonly seen presentation and is best recognized clinically. Less commonly, mesothelioma can arise from epithelial cells lining other visceral cavities, including the … [Read more...]
Prognostic importance of the neutrophil-to-lymphocyte ratio in malignant peritoneal mesothelioma patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Background: Malignant peritoneal mesothelioma (MPM) is a rare but aggressive cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was the preferred choice for selected patients. The purpose of this study was to thoroughly examine the impact of the combined treatment and the prognostic variables, particularly the … [Read more...]
Long Road to Identifying Peritoneal Mesothelioma: An Elusive Diagnosis
Peritoneal mesothelioma is a rare and aggressive malignancy [ of the peritoneum ] that often presents with non-specific abdominal symptoms such as ascites, leading to delayed diagnosis and treatment. It poses significant diagnostic challenges, especially in the absence of classical risk factors like asbestos exposure. We report the case of a … [Read more...]
- 1
- 2
- 3
- …
- 8
- Next Page »